Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
Authors:
- A. Keith StewartASA. Keith Stewart
- Meletios A. DimopoulosMeletios A. Dimopoulos
- Tamás MassziTMTamás Masszi
- Ivan ŠpičkaIŠIvan Špička
- Albert OriolAOAlbert Oriol
- Roman HájekRHRoman Hájek
- Laura RosiñolLRLaura Rosiñol
- David S. SiegelDSDavid S. Siegel
- Ruben NiesvizkyRNRuben Niesvizky
- Andrzej J. JakubowiakAJAndrzej J. Jakubowiak
- Jesus F. San-MiguelJSJesus F. San-Miguel
- Heinz LudwigHLHeinz Ludwig
- 10 November 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (32) , 3921-3930
Abstract
Purpose: To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial. Methods: Patients with relapsed multiple myeloma were randomly assigned to receive KRd or Rd. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and myeloma-specific module were administered at baseline; day 1 of cycles 3, 6, 12, and 18; and after treatment. The Global Health Status/Quality of Life (GHS/QoL) scale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning, disease symptoms, and adverse effects of treatment) were compared between groups using a mixed model for repeated measures. The percentages of responders with ≥ 5- or 15-point GHS/QoL improvement at each cycle were compared between groups. Results: Baseline questionnaire compliance was excellent (94.1% of randomly assigned patients). KRd patients had higher GHS/QoL scores versus Rd patients over 18 treatment cycles (two-sided P < .001). The minimal important difference was met at cycle 12 (5.6 points) and approached at cycle 18 (4.8 points). There was no difference between groups for the other prespecified subscales from ASPIRE. A higher proportion of KRd patients met the GHS/QoL responder definition (≥ 5-point improvement) with statistical differences at cycle 12 (KRd v Rd patients, 25.5% v 17.4%, respectively) and 18 (KRd v Rd patients, 24.2% v 12.9%, respectively). Conclusion: KRd improves GHS/QoL without negatively affecting patient-reported symptoms when compared with Rd. These data further support the benefit of KRd in patients with relapsed multiple myeloma.Keywords
This publication has 27 references indexed in Scilit:
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2015
- Review of health-related quality of life data in multiple myeloma patients treated with novel agentsLeukemia, 2013
- Responsiveness and minimal important score differences in quality‐of‐life questionnaires: a comparison of the EORTC QLQ‐C30 cancer‐specific questionnaire to the generic utility questionnaires EQ‐5D and 15D in patients with multiple myelomaEuropean Journal of Haematology, 2011
- An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myelomaEuropean Journal of Cancer, 2007
- Health related quality of life in patients with multiple myeloma undergoing a double transplantationEuropean Journal of Haematology, 2005
- Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differencesEuropean Journal of Haematology, 2004
- Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell SupportMedical Oncology, 2001
- Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myelomaBritish Journal of Haematology, 1999
- Measurement of health‐related quality of life in multiple myelomaBritish Journal of Haematology, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993